Insider Selling: Precision BioSciences, Inc. (NASDAQ:DTIL) Insider Sells 10,287 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) insider J. Jefferson Smith sold 10,287 shares of Precision BioSciences stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the sale, the insider now directly owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. This represents a 10.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Precision BioSciences Price Performance

NASDAQ:DTIL opened at $5.00 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The company has a 50 day moving average price of $5.56 and a 200-day moving average price of $8.01. Precision BioSciences, Inc. has a 1-year low of $3.61 and a 1-year high of $19.43. The firm has a market cap of $38.35 million, a price-to-earnings ratio of 83.35 and a beta of 1.51.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC lifted its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the quarter. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Analyst Ratings Changes

DTIL has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a report on Friday, January 10th. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a research note on Friday, January 10th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.